Health-Economic Comparison of Sensor-Augmented Pump With Low Glucose Suspend Versus Insulin Pump Alone For The Treatment Of Hypo-Prone Type 1 Diabetes In Slovakia

  • Roze S
  • Lynch P
  • Machova R
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Objectives: To project the long-term costs and outcomes of sensor-augmented pump (SAP) with low glucose suspend (LGS) versus insulin pump (CSII) alone for the treatment of hypo-prone Type 1 diabetes in Hungary. Methods: The CORE Diabetes Model is a peer-reviewed, validated model, which employs standard Markov/Monte Carlo simulation techniques to describe the long-term incidence and progression of diabetes-related complications. It was used to simulate disease progression in a cohort of patients with baseline characteristics (mean age 18.6 years, duration of diabetes 12 years, mean HbA1c 7.5%) and clinical outcomes (severe hypoglycaemic event rates; Quality of Life; HbA1c) taken from a recent randomised controlled trial (Ly et al, 2013). Local treatment and complication cost data was used. The main scenario considered in this cost-effectiveness analysis was the comparison of sensor-augmented insulin pump (SAP) with low glucose suspend (LGS) versus pump alone (CSII). The target population was hypo-prone type I diabetes patients with the analysis based on a deterministic microsimulation of 1,000 patients, using a 1 to 5 year time horizon. Direct costs were calculated from a third-party payer perspective. Discount rates of 3.7% per annum were applied to both costs and clinical outcomes. Results: The Incremental-Cost-Effectiveness-Ratio (ICER) for SAP+LGS vs CSII was HUF 6,196,086 ( 20,298) per Quality-Adjusted-Life-Year gained over a 1 year time horizon. Results were similar using a 5 year time horizon (HUF 6,125,823 [ 20,068] per QALY gained). Extensive sensitivity analyses showed the robustness of the results. Conclusions: Using a payer's perspective, our analysis showed that SAP (w LGS) is cost-effective over a short term (1-5 year) time horizon in hypo prone patients with Type 1 Diabetes in Hungary (using a WTP threshold of 3x Hungary GDP).

Cite

CITATION STYLE

APA

Roze, S., Lynch, P., Machova, R., Micieta, V., Dunne, N., Klots, M., … Martinka, E. (2014). Health-Economic Comparison of Sensor-Augmented Pump With Low Glucose Suspend Versus Insulin Pump Alone For The Treatment Of Hypo-Prone Type 1 Diabetes In Slovakia. Value in Health, 17(7), A345–A346. https://doi.org/10.1016/j.jval.2014.08.702

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free